Current studentsExisting staffContact us
 

Translating evidence of HDL and plaque regression

Simple item page
dc.contributor.authorDi Bartolo, B.
dc.contributor.authorPsaltis, P.
dc.contributor.authorBursill, C.
dc.contributor.authorNicholls, S.
dc.date.issued2018
dc.description.abstractConsiderable evidence from preclinical and population studies suggests that HDLs (high-density lipoproteins) possess atheroprotective properties. Reports from HDL infusion studies in animals and early clinical imaging trials reported evidence of plaque regression. These findings have stimulated further interest in developing new agents targeting HDL. However, the results of more recent imaging studies in the setting of high-intensity statin use have been disappointing. As the concept of plaque changes with HDL therapeutics evolves and imaging technology to evaluate these effects advances, there will become increasing opportunity to determine the effects of HDL agents on atherosclerotic plaque (Graphic Abstract).
dc.description.statementofresponsibilityBelinda A. Di Bartolo, Peter J. Psaltis, Christina A. Bursill, Stephen J. Nicholls
dc.identifier.citationArteriosclerosis, Thrombosis, and Vascular Biology, 2018; 38(9):1961-1968
dc.identifier.doi10.1161/ATVBAHA.118.307026
dc.identifier.issn1079-5642
dc.identifier.issn1524-4636
dc.identifier.orcidDi Bartolo, B. [0000-0001-8420-0461]
dc.identifier.orcidPsaltis, P. [0000-0003-0222-5468]
dc.identifier.orcidBursill, C. [0000-0002-0682-8760] [0000-0003-1087-7781]
dc.identifier.orcidNicholls, S. [0000-0002-9668-4368]
dc.identifier.urihttp://hdl.handle.net/2440/117698
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.rights© 2018 American Heart Association, Inc.
dc.source.urihttps://doi.org/10.1161/atvbaha.118.307026
dc.subjectanimals
dc.subjectatherosclerosis
dc.subjectlipids
dc.subjectresearch
dc.subjectrisk factors
dc.titleTranslating evidence of HDL and plaque regression
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications